Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression

No abstract is available for this paper.

• Publication year

  2018

• Venue

  The FASEB Journal

• Publication date

  2018-05-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1096/fj.201800081RPMID 29723037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• development and

  2019cited by this paper
• Muscle‐specific expression of the RNA‐binding protein Staufen1 induces progressive skeletal muscle atrophy via regulation of phosphatase tensin homolog

  2017cited by this paper
• Pharmacological advances for treatment in Duchenne muscular dystrophy.

  2017cited by this paper
• Exon skipping: a first in class strategy for Duchenne muscular dystrophy

  2017cited by this paper
• Anti-cancer effect of low dose of celecoxib may be associated with lnc-SCD-1:13 and lnc-PTMS-1:3 but not COX-2 in NCI-N87 cells.

  2017cited by this paper
• Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns—an Alternative Viewpoint

  2017cited by this paper
• Celecoxib-induced Liver Injury: Analysis of Published Case Reports and Cases Reported to the Food and Drug Administration

  2017cited by this paper
• Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME

  2017cited by this paper
• A simple practice guide for dose conversion between animals and human

  2016cited by this paper
• Inflammatory predisposition predicts disease phenotypes in muscular dystrophy

  2016cited by this paper
• Activation of HuR downstream of p38 MAPK promotes cardiomyocyte hypertrophy.

  2016cited by this paper
• Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors

  2016cited by this paper
• Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies

  2016cited by this paper
• Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

  2016cited by this paper
• Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy.

  2015cited by this paper
• Utrophin A is essential in mediating the functional adaptations of mdx mouse muscle following chronic AMPK activation.

  2015cited by this paper
• Second-generation compound for the modulation of utrophin in the therapy of DMD

  2015cited by this paper
• Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers

  2015cited by this paper
• Cis-Acting Sequence Elements and Upstream Open Reading Frame in Mouse Utrophin-A 5'-UTR Repress Cap-Dependent Translation

  2015cited by this paper
• Metformin increases peroxisome proliferator–activated receptor γ Co‐activator‐1α and utrophin a expression in dystrophic skeletal muscle

  2015cited by this paper
• Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis.

  2014cited by this paper
• Muscle-Specific SIRT1 Gain-of-Function Increases Slow-Twitch Fibers and Ameliorates Pathophysiology in a Mouse Model of Duchenne Muscular Dystrophy

  2014cited by this paper
• Pro‐Inflammatory macrophages increase in skeletal muscle of high fat‐Fed mice and correlate with metabolic risk markers in humans

  2014cited by this paper
• Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2

  2014cited by this paper
• Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy

  2014cited by this paper
• Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress.

  2014cited by this paper
• Implantation of the HeartMate II and HeartWare Left Ventricular Assist Devices in Patients With Duchenne Muscular Dystrophy: Lessons Learned From the First Applications

  2014cited by this paper
• Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.

  2013influential reference
• Identification of New Dystroglycan Complexes in Skeletal Muscle

  2013cited by this paper
• Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNA-binding protein KSRP and inhibition of AU-rich element-mediated mRNA decay: implications for novel DMD therapeutics.

  2013cited by this paper
• A Cell-Based High-Throughput Screening Assay for Posttranscriptional Utrophin Upregulation

  2013cited by this paper
• Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.

  2013cited by this paper
• Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy.

  2013cited by this paper
• Cardiac and Respiratory Dysfunction in Duchenne Muscular Dystrophy and the Role of Second Messengers

  2013cited by this paper
• TLR2 and TLR4 activate p38 MAPK and JNK during endurance exercise in skeletal muscle.

  2012cited by this paper
• Inflammation in muscular dystrophy and the beneficial effects of non‐steroidal anti‐inflammatory drugs

  2012cited by this paper
• Functional interplay between RNA-binding protein HuR and microRNAs.

  2012cited by this paper
• Celecoxib pathways: pharmacokinetics and pharmacodynamics.

  2012cited by this paper
• Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle.

  2011cited by this paper
• Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse

  2011cited by this paper
• Effects of celecoxib on major prostaglandins in asthma

  2011cited by this paper
• RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation

  2011cited by this paper
• Drug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation Screening

  2011cited by this paper
• The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

  2011cited by this paper
• Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications

  2011cited by this paper
• Therapeutic approaches to muscular dystrophy.

  2011cited by this paper
• Novel Actions of Nonsteroidal Anti-Inflammatory Drugs on Vascular Ion Channels: Accounting for Cardiovascular Side Effects and Identifying New Therapeutic Applications.

  2010cited by this paper
• Ventilatory parameters and maximal respiratory pressure changes with age in Duchenne muscular dystrophy patients

  2010cited by this paper
• Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice

  2010cited by this paper
• Change in Natural History of Duchenne Muscular Dystrophy With Long-term Corticosteroid Treatment: Implications for Management

  2010cited by this paper
• Differential Expression of Utrophin‐A and ‐B Promoters in the Central Nervous System (CNS) of Normal and Dystrophic mdx Mice

  2010cited by this paper
• The utrophin A 5'-UTR drives cap-independent translation exclusively in skeletal muscles of transgenic mice and interacts with eEF1A2.

  2010cited by this paper
• Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

  2010cited by this paper
• p38 Mitogen-Activated Protein Kinase- and HuR-Dependent Stabilization of p21Cip1 mRNA Mediates the G1/S Checkpoint

  2009cited by this paper
• COX-2 inhibitor reduces skeletal muscle hypertrophy in mice.

  2009cited by this paper
• Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor δ

  2009cited by this paper
• Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.

  2009cited by this paper
• p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR.

  2009cited by this paper
• IRES-Mediated Translation of Utrophin A Is Enhanced by Glucocorticoid Treatment in Skeletal Muscle Cells

  2008cited by this paper
• Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

  2008cited by this paper
• Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice.

  2008cited by this paper
• Identification and characterization of infiltrating macrophages in acetaminophen‐induced liver injury

  2008cited by this paper
• Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

  2008cited by this paper
• Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells.

  2007cited by this paper
• Role of AMPKalpha2 in basal, training-, and AICAR-induced GLUT4, hexokinase II, and mitochondrial protein expression in mouse muscle.

  2007cited by this paper
• Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.

  2006cited by this paper
• AMP-Activated Protein Kinase-Regulated Activation of the PGC-1α Promoter in Skeletal Muscle Cells

  2006cited by this paper
• Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses.

  2006cited by this paper
• Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies

  2005cited by this paper
• The Utrophin A 5′-Untranslated Region Confers Internal Ribosome Entry Site-mediated Translational Control during Regeneration of Skeletal Muscle Fibers*

  2005cited by this paper
• Systemic delivery of genes to striated muscles using adeno-associated viral vectors

  2004cited by this paper
• Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle

  2004cited by this paper
• ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan.

  2004cited by this paper
• Heregulin ameliorates the dystrophic phenotype in mdx mice.

  2004cited by this paper
• Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse.

  2004cited by this paper
• Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF‐AT pathway

  2004cited by this paper
• Regulation of Muscle Fiber Type and Running Endurance by PPARδ

  2004cited by this paper
• Therapeutics for Duchenne muscular dystrophy: current approaches and future directions

  2004cited by this paper
• Pharmacological strategies for muscular dystrophy

  2003cited by this paper
• Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers.

  2002cited by this paper
• Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models.

  2002cited by this paper
• Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system.

  2002cited by this paper
• A- and B-utrophin Have Different Expression Patterns and Are Differentially Up-regulated in mdx Muscle*

  2002cited by this paper
• The dystrophin-associated protein complex.

  2002cited by this paper
• Function and genetics of dystrophin and dystrophin-related proteins in muscle.

  2002cited by this paper
• The role of utrophin in the potential therapy of Duchenne muscular dystrophy.

  2002cited by this paper
• Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events.

  2001cited by this paper
• Molecular basis of muscular dystrophies

  2000cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib

  2000cited by this paper
• Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle.

  2000cited by this paper
• Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey

  2000cited by this paper
• Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human

  1999cited by this paper
• Duchenne dystrophy: Electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber

  1998cited by this paper
• Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.

  1998cited by this paper
• Cyclooxygenase in biology and disease

  1998cited by this paper
• Differential Membrane Localization and Intermolecular Associations of α-Dystrobrevin Isoforms in Skeletal Muscle

  1998cited by this paper
• Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice

  1998cited by this paper
• Expression of full-length utrophin prevents muscular dystrophy in mdx mice

  1998cited by this paper
• Animal Models for Muscular Dystrophy Show Different Patterns of Sarcolemmal Disruption

  1997cited by this paper
• Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene

  1996cited by this paper

• Inhibiting Myozenin 1 Attenuated Muscular Dystrophy Pathology in mdx Mice by Enhancing Calcineurin Activity

  2026cites this paper
• Aminoguanidine hemisulfate improves mitochondrial autophagy, oxidative stress, and muscle force in Duchenne muscular dystrophy via the AKT/FOXO1 pathway in mdx mice

  2025cites this paper
• Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy

  2024cites this paper
• Computational Drug Discovery in Diaphragm dysfunction via Text Mining and Biomedical Database.

  2024cites this paper
• Celecoxib attenuates hindlimb unloading-induced muscle atrophy via suppressing inflammation, oxidative stress and ER stress by inhibiting STAT3

  2024cites this paper
• Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy

  2023cites this paper
• Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.

  2023cites this paper
• Pharmacological inhibition of HDAC6 downregulates TGF-β via Smad2/3 acetylation and improves dystrophin-deficient muscles

  2022cites this paper
• Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy

  2022cites this paper
• Celecoxib alleviates denervation-induced muscle atrophy by suppressing inflammation and oxidative stress and improving microcirculation.

  2022cites this paper
• Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy

  2022cites this paper
• Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation

  2022cites this paper
• The PKA-p38MAPK-NFAT5-Organic Osmolytes Pathway in Duchenne Muscular Dystrophy: From Essential Player in Osmotic Homeostasis, Inflammation and Skeletal Muscle Regeneration to Therapeutic Target

  2021cites this paper
• Contraction-Induced Loss of Plasmalemmal Electrophysiological Function Is Dependent on the Dystrophin Glycoprotein Complex

  2021cites this paper
• Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases

  2021cites this paper
• Current Pharmacological Strategies for Duchenne Muscular Dystrophy

  2021cites this paper
• Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies

  2021influential citation
• Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy

  2020cites this paper
• Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles

  2020cites this paper
• New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics

  2020cites this paper
• Muscle-Specific Deletion of SLK/Stk2 Enhances p38 Activity and Myogenesis in mdx Mice.

  2020cites this paper
• Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid

  2019cites this paper
• Utrophin A Upregulation by FDA-Approved Drugs for the Treatment of Duchenne Muscular Dystrophy

  2019cites this paper